丨Bloomage Biotech's Health Food Headquarters Officially Settles in Hangzhou Medical Port
Recently, Bloomage Biotech successfully held a signing ceremony with Qiantang (New) District of Hangzhou, marking the official settlement of Bloomage Biotech's health food headquarters project in Hangzhou Medical Port.
As a key provincial and municipal investment promotion project, the Bloomage Biotech Health Food Headquarters project, which was signed this time, will rely on synthetic biology technology to focus on the research and development, production, and sales of health food and functional food. It is reported that the total investment of this project exceeds 1 billion yuan, with fixed asset investment expected to be around 200 million yuan, and the rest being working capital, etc. The project covers an area of 21,500 square meters, integrating R&D, production, and market transformation. After full production, it is expected to have nine production lines, covering various food dosage forms such as liquid, powder, tablets, and capsules. When operating at full capacity, the annual output value is expected to reach 5 billion yuan and is expected to create employment opportunities for hundreds of high-tech R&D and production personnel.丨XtalPi Officially Listed on HKEX
6Month13XtalPi Holdings Limited officially listed on the Hong Kong Stock Exchange in the morning.This issuance attracted nearly80A global investment institution participated in the anchor investment, including well-known international long-term investors, medical special funds, and hedge funds from Europe, America, and the Middle East. The stock price continued to rise after the opening.20%, with a market value exceeding200HKD billion.Behind the company are three post-80s physicists——Shuhao Wen, Jian Ma, and Lipo Lai. In 2015, they returned to China from MIT together and founded XtalPi in Shenzhen, an innovative R&D platform driven by artificial intelligence and robotics. Since its establishment, XtalPi has become the AI pharmaceutical project with the largest amount of financing in the field, raising over 5 billion yuan cumulatively along the way and assembling a star-studded team of investors.This is the first company to go public through the 18C Specialized Technology Rules.Source: Investment Circle
丨Illegal Sale of Botulinum Toxin: Defendant Sentenced for Violating Pharmaceutical Management Regulations
Recently, the Qing County People's Court of Hebei Province announced the verdict on a case of obstructing drug management. The defendant Pan was sentenced to four months of detention, with a one-year suspended sentence, fined 10,000 yuan, and prohibited from engaging in beauty industry business activities during the probation period.According to the court's investigation, between July 2019 and May 2022, the defendant Pan purchased 116 bottles of botulinum toxin from a seller in 14 separate transactions. Apart from personal use, Pan also sold and administered injections to beauty clients, making a profit of 3,000 yuan. The defendant Pan’s sale of medical toxic drugs without obtaining a drug registration certificate posed a serious risk to human health, constituting the crime of obstructing pharmaceutical management. In view of the fact that Pan's actions did not cause adverse consequences to clients, and considering mitigating factors such as self-surrender, full restitution, and pleading guilty, along with an assessment report provided by the community correction agency, the aforementioned verdict was reached. The defendant Pan expressed acceptance of the ruling.
Source of Information:China Court Network
